Moderna and Merck's Cancer Trial Sparks Healthcare Sector Rally
The healthcare sector experienced its strongest week since June, driven by positive results from a late-stage clinical trial involving Moderna (NASDAQ:MRNA) and Merck & Co. (NYSE:MRK). The companies announced that their personalized mRNA cancer treatment significantly improved recurrence-free survival in melanoma patients compared to Keytruda alone. The Phase 3 INTerpath-001 trial tested intismeran autogene, a tailored vaccine combined with Keytruda, and met both primary endpoints. Researchers called the results landmark for validating neoantigen vaccines as an effective cancer treatment strategy. Moderna's stock surged over 177% on the news, while Merck saw a more modest but notable increase. The positive trial outcomes reignited investor enthusiasm across the healthcare sector, with two-thirds of health-care stocks rising that week. The results also signaled renewed confidence in mRNA technology beyond vaccines and highlighted potential for broader cancer applications.
Topics: Biotech Innovation Cancer mRNA Therapy Pharmaceuticals